Peroxisome Proliferator-Activated Receptors Increase Human Sebum Production  by Trivedi, Nishit R. et al.
Peroxisome Proliferator-Activated Receptors Increase
Human Sebum Production
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Surendra Sivarajah4, Kathryn L. Gilliland1, Wenlei Liu5, David T. Mauger5, Robert A. Gabbay4 and
Diane M. Thiboutot1,3
Sebum production is key in the pathophysiology of acne, an extremely common condition, which when severe,
may require treatment with isotretinoin, a known teratogen. Apart from isotretinoin and hormonal therapy, no
agents are available to reduce sebum. Increasing our understanding of the regulation of sebum production is a
milestone in identifying alternative therapeutic targets. Studies in sebocytes and human sebaceous glands
indicate that agonists of peroxisome proliferator-activated receptors (PPARs) alter sebaceous lipid production.
The goal of this study is to verify the expression and activity of PPARs in human skin and SEB-1 sebocytes and to
assess the effects of PPAR ligands on sebum production in patients. To investigate the contribution of each
receptor subtype to sebum production, lipogenesis assays were performed in SEB-1 sebocytes that were treated
with PPAR ligands and isotretinoin. Isotretinoin significantly decreased lipogenesis, while the PPARa agonist-
GW7647, PPARd agonist-GW0742, PPARa/d agonist-GW2433, PPARg agonist rosiglitazone, and the pan-agonist-
GW4148, increased lipogenesis. Patients treated with thiazolidinediones or fibrates had significant increases in
sebum production (37 and 77%, respectively) when compared to age-, disease-, and sex-matched controls.
These data indicate that PPARs play a role in regulating sebum production and that selective modulation of their
activity may represent a novel therapeutic strategy for the treatment of acne.
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INTRODUCTION
Acne is a common condition affecting millions of patients
worldwide. Although not life-threatening, it can lead to
feelings of low self-esteem and permanent facial scarring. The
pathophysiology of acne centers on the interplay of follicular
hyperkeratinization, inflammation induced by Propionibac-
terium acnes and the production of sebum that serves as a
nutrient source for P. acnes (Zouboulis, 2001, 2004;
Zouboulis and Degitz, 2004). Sebum production is essential
to the development of acne. Only isotretinoin (13-cis retinoic
acid (13-cis RA)) and hormonal therapy reduce sebum
production. With increasing concerns regarding teratogeni-
city, there is a clear need for therapeutic alternatives to
isotretinoin in the treatment of acne.
A series of key experiments demonstrated that co-
administration of androgens with ligands of peroxisome
proliferator-activated receptors (PPARs) augments the intra-
cellular accumulation of lipids in sebaceous gland-like cells
of rat preputial gland (Rosenfield et al., 1999). This
observation coupled with the many similarities that exist
between adipogenesis and sebaceous lipogenesis led to the
hypothesis that PPARs may be important in the regulation of
human sebum production and the development of acne
(Rosenfield et al., 2000; Kim et al., 2001; Zouboulis et al.,
2005). PPARs are members of the nuclear hormone receptor
family that form heterodimers with retinoid X receptors and
act as transcriptional regulators of a variety of genes including
those involved in lipid metabolism in adipose tissue, liver and
skin (Rosen and Spiegelman, 2001; Ferre, 2004; Knouff and
Auwerx, 2004). As with retinoid receptors, there are three
subclasses of PPARs: a, d, and g, which differ in their tissue
localization and in their transcriptional activities (Berger and
Moller, 2002; Desvergne et al., 2004; van Raalte et al., 2004).
PPARa receptors are expressed in numerous tissues in
humans including liver, kidney, heart, skeletal muscle, fat,
and endothelial cells (Braissant et al., 1996). PPARa has been
shown to play a critical role in the regulation of cellular
uptake, activation and b-oxidation of fatty acids. The most
commonly used exogenous PPARa agonists are the fibrates
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that are clinically used for the treatment of hyperlipidemia
(Fazio and Linton, 2004). Fibrates effectively reduce plasma
triglycerides in patients by mediating increased lipid uptake
and transcriptional modulation of numerous genes that
regulate these processes (Motojima et al., 1998). PPARa
agonists have been shown to amplify the expression of
lipoprotein lipase and inhibit apolipoprotein C-III in the liver
(Schoonjans et al., 1996). However, the exact action of
PPARa agonists on lipid metabolism is relatively complex and
has been shown to vary in different cellular systems. PPARd is
widely expressed in a wide range of tissues and cells with
relatively higher levels found in the brain, adipose tissue, and
skin. Recently, compounds that interact with PPARd recep-
tors have been shown to increase differentiation and
lipogenesis in epidermal keratinocytes (Westergaard et al.,
2001; Schmuth et al., 2004). PPARg is predominantly located
in adipose tissue. There is strong evidence that PPARg is key
in promoting adipocyte differentiation. Treatment of fibro-
blasts with ligands of PPARg induces adipogenesis and
increases lipid production; effects resulting from the induc-
tion of adipogenic target genes (Sandouk et al., 1993; Mao-
Qiang et al., 2004). PPARs are also expressed in an
immortalized human sebocyte cell line (SZ95) and treatment
of these cells with linoleic acid, a ligand for PPARd and
PPARg, also increases the intracellular content of lipids (Chen
et al., 2003). In contrast, treatment of isolated human
sebaceous glands with some ligands of PPARa and PPARg
decreases lipogenesis (Downie et al., 2004). Studies to date
have not investigated the effects of PPAR ligands on human
sebum production, which is key in the pathophysiology of
acne. The goals of this study were: (1) to confirm the
localization of PPAR subtypes in human skin, as currently
shown (Alestas et al., 2006), and to determine their presence
and localization in SEB-1 sebocytes; (2) to compare the
effects of a panel of potent and isoform-specific PPAR
agonists and antagonist with the known inhibitory effects of
13-cis RA on lipogenesis in SEB-1 cells and (3) to test the
hypothesis that PPAR ligands (thiazolidinediones and fibrates)
alter sebum production in patients treated for diabetes or
hyperlipidemia.
RESULTS
PPARs are expressed in human skin and SEB-1 cells
The role of PPAR receptors and the effects of their subtype-
specific ligands in regulating the lipid metabolism in the liver
and adipose tissue have been well documented. Since our
study was aimed at examining the effects of subtype specific
PPAR ligands on human sebum production, we initially
examined the presence and pattern of distribution of each of
these receptor subtypes in normal human skin as well as in
our SEB-1 sebocyte cell line. Immunohistochemistry of
sections of whole skin revealed expression of each of the
PPAR subtypes in epidermis, hair follicles, sebaceous ducts
and sebaceous glands (Figure 1, representative of data from
five subjects). Reactivity within the epidermis was most
prominent with PPARa and PPARg (Figure 1b and d). In
examining expression within the sebaceous gland, each
antibody reacted with basal sebocytes (Figure 1b–d, insets).
PPARg expression however was also noted within differen-
tiated sebocytes. PPAR expression was also examined in
undifferentiated SEB-1 sebocytes (30% confluent) and in SEB-
1 sebocytes that were differentiated by treating with insulin
and growing to confluence (Figure 2). Under both conditions,
PPARa immunoreactivity was perinuclear. In the undiffer-
entiated state, PPARd reactivity was perinuclear but distinctly
nuclear in the differentiated state. PPARg immunoreactivity
was perinuclear in undifferentiated cells with more nuclear
reactivity noted in differentiated cells.
Patients receiving fibrates (PPARa ligands) for hyperlipidemia or
thiazolidinediones (PPARc ligands) for diabetes have increased
sebum secretion compared to age-, sex-, and disease-matched
controls
To analyze the effects of subtype-specific PPAR ligands on
sebum secretion we studied a sample of patients receiving
fibrates (PPARa ligands) for hyperlipidemia or thiazolidine-
diones (PPARg ligands) for diabetes. Interim analyses of the
data were performed after 1 year of subject recruitment and
the study was terminated. A total of 45 patients receiving
thiazolidinediones and 45 age-, sex-, and disease-matched
controls were enrolled and analyzed (Table 1). Twenty-seven
patients in the treatment group were receiving pioglitazone
and 18 were receiving rosiglitazone. Most patients in both
the thiazolidinedione and control groups were receiving
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Figure 1. PPAR isoforms localize to epithelia in normal human skin. (b–d,
respectively) Immunoreactivity to PPARa, d, and g subtypes is noted in
epidermis, hair follicle, and sebaceous gland as a brown to red color. Insets
demonstrate reactivity in basal cells of the sebaceous gland with expression of
PPARg extending to differentiated sebaceous cells. (a) Negative controls were
treated with nonimmune serum in place of primary antibody. (a–d)
Bar¼200 mm.
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additional treatments including insulin, oral hypoglycemic
drugs, ACE inhibitors, and statins. There were no statistical
differences between treatment and control groups in terms of
renal function, presence of vascular disease, or hemoglobin
A1C. Patients in the treatment group had significantly greater
body mass index (Po0.0001) reflecting a predominance of
type II diabetes. Patients in the control group reported a
longer duration of diabetes (P¼ 0.05). Subjects taking
thiazolidinediones for at least 3 months had an approximate
37% increase in mean sebum secretion as compared to
controls (P¼ 0.017). A total of 14 subjects receiving
treatment with fibrates and 14 age-, sex-, and disease-
matched controls were enrolled. Seven patients were
receiving fenofibrate and seven were receiving gemfibrizol.
The majority of patients in both the treatment group and
the control group were also receiving treatment with drugs
of the statin class, beta-blockers, and ACE inhibitors. There
were no differences between treatment and control groups
in terms of duration of hyperlipidemia or total cholesterol.
Triglycerides were significantly higher in the treatment group
(P¼0.004), as might be anticipated in a group requiring
fibrates. The subjects taking fibrates had an approximate 77%
increase in mean sebum secretion compared with controls
(P¼0.023).
PPAR agonists and 13-cis RA have differential effects
on sebaceous gland lipogenesis and each alter the pattern
of sebaceous lipids produced
In order to observe the differences in lipid production
following treatment of SEB-1 sebocytes with the novel PPAR
subtype-specific ligands and 13-cis RA, lipogenesis assays
were performed. The effects of PPAR ligands and 13-cis RA
on the overall incorporation of 14C-acetate into sebaceous
lipids are depicted in Table 2. Significant increases in the
total production of neutral lipids were noted with the PPARa
agonist GW7647, PPARd agonist GW0742, PPARa/d agonist
GW2433, PPARg agonist rosiglitazone, and the PPARa, d,
and g agonist GW4148 (Figure 3). However no significant
differences were seen following treatment with PPARg
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Figure 2. PPAR subtypes are expressed in SEB-1 sebocytes. SEB-1
sebocytes were grown to 30% confluence (undifferentiated) or were treated
with 1 mM insulin and grown to confluence (differentiated). PPARa
immunoreactivity is perinuclear under both conditions. PPARd reactivity
is perinuclear in the undifferentiated cells and nuclear in differentiated
cells. PPARg reactivity was perinuclear and cytoplasmic under both
condition. Negative control sections incubated with nonimmune serum
in place of primary antibody. Bar¼ 50 mm.
Table 1. Increased sebum secretion in patients treated with the PPAR ligands: thiazolidinediones and fibrates
TZD, N=45
TZD: control group,
N=45
Fibrate,
N=14
Fibrate: control group,
N=14
Mean age7SD 51.279 49712 5477.7 5576.7
Male 25 25 10 10
Female 20 20 4 4
Mean sebum secretion (mg/cm27SD) 92757 67737 131755 74737
P-value, unpaired t-test, a=0.05 0.017 0.023
Fold increase in sebum drug
treated versus control
1.37 1.77
TZD, thiazolidinediones.
Levels of the skin surface sebum in patients treated with TZD class of drugs (PPARg agonists – rosiglitazone and pioglitazone) or the fibrate class of drugs
(PPARa agonists – gemfibrizol and fenofibrate) when compared to age-, sex-, and disease-matched control patients. Sebum levels were measured using a
Sebumeter SM 810s from three different sites on the forehead of each patient. Statistical analysis was performed using an unpaired t-test.
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agonist pioglitazone. In contrast, treatment of SEB-1 cells
with 13-cis RA for 24 or 72 hours resulted in significant
decreases in lipid production compared to untreated cells
(Table 2) and a decrease in intracellular lipid as detected with
Oil Red O staining (Figure 4). We also tested the effect of an
antagonist of PPARg GW0072 on total lipid production,
however, no statistically significant changes in total lipid
production were seen (data not shown).
In addition to analyzing changes in total lipid production,
changes in each individual lipid were also analyzed. Results
for PPARa/d agonist GW2433, PPARa/d/g agonist GW4148,
PPARg agonist rosiglitazone, and 13-cis RA are shown in
Figure 3. The PPARa/d agonist GW2433, PPARa/d/g agonist
GW4148, and the PPARg agonist rosiglitazone caused a
statistically significant increase in the incorporation of acetate
into cholesterol and fatty alcohols, indicating an effect on
both the cholesterol and fatty acid biosynthetic pathways. In
addition the PPARg agonist rosiglitazone, caused a statisti-
cally significant increase in the levels of triglyceride (68%)
when compared to vehicle treated control. In contrast, 13-cis
RA decreased acetate incorporation into lipids derived from
both the cholesterol and fatty acid biosynthetic pathways.
DISCUSSION
Acne is the most common skin condition affecting young
people. Acne treatment is limited by the lack of effective
agents that reduce sebum apart from isotretinoin and from
hormonal therapy in women. With concerns regarding issues
of teratogenicity with isotretinoin, alternative means of reduc-
ing sebum production are clearly needed. Developments in
Table 2. Effect of various PPAR ligands on total lipid production in SEB-1 cells
Total lipid production (CPM/106 cells/hour7SE)
Compound Untreated Treated P-value (ANOVA)
GW7647 (a agonist) 100 nM 1,237751 1,525755 0.005
Fenofibrate (a agonist) 1 mM 1,170739 1,201734 NS
GW0742 (a/d agonist) 100 nM 1,303744 1,453740 0.0470
GW2433 (a/d agonist) 100 nM 1,670759 1,917741 0.0270
Rosiglitazone (g agonist) 10 mM 1,625735 3,252742 0.0002
Pioglitazone (g agonist) 10 mM 1,625735 1,381718 NS
GW4148 (a/d/g pan agonist) 1 mM 1,460767 1,730773 0.01
13-cis RA 1mM 1,084764 830750 0.0012
ANOVA, analysis of variance; 13-cis RA, 13-cis retinoic acid.
The amount of lipid produced following 6 days of incubation with the various PPAR compounds was determined by performing the lipogenesis assay and the
average of three separate experiments was used to quantify the differences between ligand-treated cells versus vehicle-treated controls. Significant increases
in the total production of neutral lipids were noted with the PPARa agonist GW7647 (100 nM), PPARd agonist GW0742 (100 nM), PPARa agonist GW2433
(100 nM), PPARg agonist rosiglitazone (10 mM), and the PPARa/d/g agonist GW4 148 (1 mM). An inverse relationship was seen following treatment of SEB-1
cells with 13-cis RA (1 mM), which showed a significant decrease in total lipid produced at 72 hours.
*
*
*
* *
*
*
*
*
*
*
*
3.5
2.5
1.5
0.5
0
1
2
3
Li
pi
d 
pr
od
uc
tio
n
(fo
ld
 c
ha
ng
e 
fro
m
 c
on
tro
l)
Ch
ol
es
te
ro
l
Ch
ol
es
te
ro
l
e
st
er
Fa
tty
 a
lco
ho
l
Fa
tty
 a
cid
Tr
ig
lyc
er
id
e
Sq
ua
le
ne
*P< 0.01
Vehicle
GW2433
GW4148
Rosiglitazone
13-cis RA
Figure 3. PPAR agonists and 13-cis RA alter the pattern of lipid production
in SEB-1 sebocytes. SEB-1 sebocytes were grown in SEB-1 medium until they
reached 90% confluence then treated with PPARa/d agonist GW2433
(100 nM), PPARa/d/g agonist GW4148 (1 mM), Rosiglitazone (10 mM) every
48 hours until the 6th day to study the differential pattern of lipid production.
Cells were treated with 13-cis RA (1 mM) for 72 hours. Statistically significant
increases were noted in the production of cholesterol and fatty acid following
treatment with PPAR agonists (GW2433, GW4148, and rosiglitazone) when
compared to vehicle-treated controls (Po0.01); whereas treatment with
13-cis RA showed a statistically significant decrease in the production of
cholesterol, fatty alcohol, cholesterol ester, and squalene (Po0.01). Values
represented are means7SE.
50 m 50 m
a b
Figure 4. Oil Red O staining of SEB-1 sebocytes indicates decreased
intracellular lipidsin SEB-1 sebocytes treated with 13-cis RA. SEB-1
sebocytes were treated with 0.1mM (a) 13-cis RA or (b) vehicle for 72 hours.
Note decrease in intracellular lipids with cells treated with 13-cis RA.
Bar¼50 mm.
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this area are dependent upon advances in our understanding
of the factors that regulate lipid production in human skin and
sebaceous glands.
Pivotal studies in rat preputial cells, SZ95 immortalized
human sebocytes, and isolated human sebaceous glands
have raised the interesting possibility that compounds acting
at PPARs can alter sebaceous lipids and, as such, may be
useful in the treatment of acne (Rosenfield et al., 1999; Chen
et al., 2003; Downie et al., 2004). To date, only initial
clinical studies with zileuton, an inhibitor of leukotriene B4
synthesis, where leukotriene B4 is a potent natural ligand of
PPARa, exist, which revealed a significant reduction of acne
lesions and sebaceous lipid synthesis (Zouboulis et al., 2003;
Zouboulis Ch et al., 2005). In this study, we confirm that
PPARs are expressed in human skin as well as sebocytes and
we demonstrate that PPAR agonists increase sebum produc-
tion in adults with diabetes and hyperlipidemia.
Each of the PPAR subtypes are expressed in rat preputial
sebocytes, SZ95 immortalized human sebocytes, human
sebaceous glands, hair follicles, and cultured human
keratinocytes (Rivier et al., 1998; Rosenfield et al., 1999;
Billoni et al., 2000; Chen et al., 2003; Downie et al., 2004).
Localization studies in whole specimens of human skin
have been completed, showing that all PPAR subtypes are
present in sebaceous glands and the pilosebaceous ducts
of both healthy and acne-involved skin (Chen et al., 2003;
Alestas et al., 2006). PPAR expression was verified in SEB-1
using immunohistochemistry. Our data confirm that each of
the PPAR subtypes is expressed in human skin where they
localize to epidermis, sebaceous glands, and hair follicles.
Each subtype is expressed in the basal layer of the sebaceous
gland with PPARg expression noted in differentiated cells
within the gland. These findings are in agreement with those
of Alestas et al. (2006), wherein each of the PPAR subtypes
was expressed within the sebaceous gland of healthy skin
and in acne-involved and uninvolved skin of subjects
with acne.
Ligands of PPARd increase lipid accumulation in murine
keratinocytes (Schmuth et al., 2004). There have been
conflicting reports, however, with regard to the effects of
PPAR ligands on sebaceous lipid production. Studies carried
out in rat preputial cells indicate that PPAR ligands such as
fibrates, linoleic acid, and thiazolidinediones increase
intracellular lipid droplets (Rosenfield et al., 1999; Chen
et al., 2003). This effect is more pronounced when cells are
simultaneously treated with dihydrotestosterone or in the
presence of an retinoid X receptor agonist (Rosenfield et al.,
1998, 1999; Kim et al., 2001). Studies carried out in SZ95
sebocytes indicate that linoleic acid, but not other ligands of
PPARa or PPARg, increase lipid production (Chen et al.,
2003). However, studies in isolated human sebaceous glands
indicate that PPAR ligands such as linoleic acid decrease
lipogenesis (Downie et al., 2004).
Since 13-cis RA is the most potent known agent for
reducing sebum production, it was used as a comparator in
the in vitro studies of the activity of PPAR ligands on
sebaceous gland lipogenesis. 13-cis RA markedly decreased
acetate incorporation into lipids, which is in agreement with
data generated in primary cultures of human sebocytes
(Zouboulis et al., 1991). This was accompanied by a decrease
in intracellular lipids as seen with Oil Red O staining. In
contrast, PPAR ligands such as the PPARa agonist GW7647,
PPARd agonist GW0742, the PPARa, d agonist GW2433,
PPARg agonist rosiglitazone, and the PPAR pan-agonist
GW4148 increased lipogenesis. The pattern of lipid synthesis
was altered by many of these compounds to favor the
incorporation of acetate into cholesterol, fatty acids, and fatty
alcohols, effects opposite to that of 13-cis RA. Rosiglitazone
induced a 68% increase in acetate incorporation into
triglycerides which supports the recent findings of increased
triglycerides in hamster sebaceous glands treated with a
similar PPARg agonist, troglitazone (Iwata et al., 2005). These
findings in cell culture are in agreement with the known
effects of PPAR ligands in upregulating many of the genes
involved in fatty acid and cholesterol biosynthesis. Apart
from possible differences in the lipogenic response to
PPARd and PPARg agonists, no biological differences were
noted between SEB-1 and SZ-95 sebocytes (Chen et al.,
2003).
A similar trend in sebum production was noted in patients
treated with PPARa and g agonists. Sebum production was
significantly greater in patients with hyperlipidemia receiving
fibrates (PPARa agonists) and in patients receiving thiazoli-
dinediones (PPARg agonists) for type II diabetes compared to
age-, sex-, and disease-matched controls. No ligands of
PPARd are approved for use in humans to allow testing of
their effects on sebum production. Although sebum is
increased, no increase in the incidence of acne has been
reported in patients who have been treated with fibrates or
thiazolidinediones. This is not surprising as these patients are
older than those affected by acne. Many older patients have
seborrhea but do not have acne. It is important to appreciate
that these data were obtained in patients with underlying
medical problems and that by virtue of their disease,
differences in body mass index, and triglyceride levels were
noted. Definitive studies in otherwise healthy subjects,
perhaps in a younger age group would be required to most
accurately assess the effects of PPAR ligands on sebum
production.
Although rosiglitazone increased lipid production in SEB-1
cells, the levels were relatively unchanged after treatment
with another PPARg agonist, pioglitazone. These data agree
with reports that show that while rosiglitazone and pioglita-
zone have similar effects in lowering glucose, they exert
significantly different effects on triglyceride, high-density
lipoprotein cholesterol, low-density lipoprotein cholesterol
particle size, and concentration (Boyle et al., 2002; Khan
et al., 2002; Goldberg et al., 2005). Of interest is the lack of
inhibition of sebocyte lipogenesis by a PPARg antagonist. The
compound GW0072 though labeled as a PPAR antagonist by
some is actually one of the first partial agonists of PPAR
activity (Oberfield et al., 1999; Berger and Moller, 2002;
Rival et al., 2004). While earlier studies described this
compound as a PPARg antagonist because of its ability to
inhibit thiazolidinedione-induced adipocyte differentiation,
more recent studies have focused on the analysis of the
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co-crystal structure of this compound with the PPARg ligand-
binding domain and highlighted a more complex mechanism
of action and termed the compound as a partial agonist
(Oberfield et al., 1999). Further studies examining the role of
PPARg partial agonists in the presence of PPARg agonists may
help to bring to light the true antagonistic properties of these
compounds.
The specific identity of the endogenous ligands that act on
PPARs in the skin is unknown. Potential ligands include fatty
acids, eicosanoids, and other lipids found in the skin and
sebaceous glands. This hypothesis is supported by pilot
observations of decreased sebum production and acne in
patients treated with zileuton, an inhibitor of lipoxygenase
enzymes that are known to result in the formation of
eicosanoids that interact with PPARs (Zouboulis et al.,
2003). Clearly additional clinical studies in varying popula-
tions of patients affected by acne will help determine whether
agonism or antagonism of specific PPAR subtypes reduces
sebum production and improves acne.
MATERIALS AND METHODS
Cell culture
The SEB-1 sebocyte cell line was produced from human sebocytes
that were transformed with SV 40 large T antigen (Thiboutot et al.,
2003). Passage 21–23 SEB-1 immortalized human sebocytes were
used in all experiments. They were cultured in standard sebocyte
medium consisting of DMEM containing 5.5 mM glucose supple-
mented with Ham’s F-12 (3:1), fetal bovine serum (2.5%), adenine
(1.8 104 M), hydrocortisone (0.4 mg/ml), insulin (10 ng/ml), epi-
dermal growth factor (3 ng/ml) and cholera toxin (1.2 1010 M) for
immunohistochemistry and assays of lipogenesis. Serum-free sebo-
cyte medium used in lipogenesis experiments consisted of DMEM
containing 5.5 mM glucose and antibiotics without any other
additives.
Antibodies
For immunohistochemistry in SEB-1 sebocytes and in formalin-
fixed, paraffin-embedded sections of the human skin, polyclonal
rabbit anti-human antibodies to PPARa, PPARd, and PPARg were
purchased from Cayman Chemical Company (Ann Arbor, MI) and
used at dilutions of 1:500, 1:250, and 1:200, respectively.
Biotinylated goat anti-rabbit secondary antibody was purchased
from Vector Laboratories Inc. (Burlingame, CA) and used at 1:200
dilution.
Immunohistochemistry
Immunohistochemistry was performed on SEB-1 sebocytes and
formalin-fixed, paraffin-embedded human skin sections using the
avidin–biotin complex method and AEC development (ABC kit and
AEC Substrate Kit for Peroxidase, Vector Laboratories Inc.; Burlin-
game, CA). Briefly, SEB-1 sebocytes were grown until 30–50%
confluent or confluent in standard medium on chamber slides before
the addition of 1mM insulin for 24 hours to correlate immunoreac-
tivity with confluency and the differentiation state of the cells. Cells
were fixed with 100% methanol. Sections of normal facial skin were
subjected to deparaffinization, rehydration, and antigen retrival prior
to immunohistochemistry. Antigen retrival was preformed using
TRILOGY buffer (Cell Marque, Hot Springs, AR).
Oil red O staining
SEB-1 (p23) sebocytes were treated with 0.1 mM 13-cis RA or vehicle
(DMSO) to determine whether these cells decrease their lipid
content in response to 13-cis RA. Cells were grown in standard
medium and were then treated with 13-cis RA or vehicle in serum-
free medium for an additional 3 days. Oil Red O staining was
performed using standard techniques and slides were counterstained
with hematoxylin.
Clinical protocols for sebum assessment in subjects treated with
PPAR ligands
The clinical protocol for the assessment of sebum in subjects
treated with PPAR ligands was approved by the Institutional
Review Board of the Pennsylvania State University College of
Medicine and was conducted in accordance with the guidelines
set forth in the Declaration of Helsinki Principles. All subjects
signed informed consent. Subjects were recruited from the
Diabetes clinic or Cardiology clinic at the Milton S. Hershey
Medical Center. Since drugs of the fibrate and thiazolidinedione
class are in use for the treatment of hyperlipidemia and diabetes,
we sought to study the effects of these drugs on sebum production
in patients receiving these medications compared to age-, sex-,
and disease-matched controls in order to provide a potential
rationale for the future study of these drugs in acne. Inclusion
criteria included men and women aged 18–65 years with diabetes
who have been taking drugs of the thiazolidinedione class
(pioglitazone or rosiglitazone), which are PPARg agonists, or
patients with hyperlipidemia who had been taking a fibrate
(gemfibrizol and fenofibrate) which are PPARa agonists. Patients
had received treatment with these agents for a minimum of 3
months. Age- and disease-matched controls were recruited from
both clinics. Subjects were excluded from the study if they were
on any form of hormonal therapy, were pregnant or breast feeding,
were previously diagnosed with hyperandrogenism or polycystic
ovary disease, or who were within 6 months of treatment with
isotretinoin as these factors could influence sebum production.
Following informed consent, subjects gave their medical history
including concomitant medications and had three sebum readings
taken from left, center, and right sides of the forehead. For diabetic
patients receiving thiazolidinediones and their matched controls
data were collected regarding duration of diabetes, hemoglobin
A1C, serum creatinine, urine albumin, body mass index, and
presence of vascular disease. For the patients in the fibrate group
and their matched controls, data on total cholesterol, triglyceride,
and duration of hyperlipidemia were collected. These clinical
parameters were examined for differences between the treatment
and control groups using an unpaired t-test, a¼ 0.05.
Sebum assessment in human subjects
An estimate of the quantity of skin surface sebum in subjects treated
with oral fibrates or oral thiazolidinediones was performed using
Sebumeter SM 810s (CourageþKhazaka Electronic, Ko¨ln, Ger-
many) that uses a photometric method of analysis of skin surface
sebum. The skin was cleansed with a 70% isopropyl alcohol swab. A
cassette containing a 0.1 mm thickness of synthetic tape is applied to
the skin for 30 seconds. The cassette head exposes a 64 mm2
measuring section of the tape. For the determination of the amount
of sebum, the measuring head is inserted into the aperture of the
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device, where a photocell measures the transparency of the tape.
The light transmission is representative of the sebum content on the
surface of the measuring area. A microprocessor calculates the
mg sebum/cm2 of the skin. Three measurements were taken from
each test area on the forehead. An average of the three test sites was
calculated and a Student’s t-test was performed to determine
differences between patients treated with thiazolidinediones versus
controls and those treated with fibrates versus controls.
PPAR ligands
GlaxoSmithKline (Research Triangle Park, NC) generously supplied
a series of subtype-specific PPAR ligands GW7647 (a agonist),
GW0742 (d agonist), GW2433 (a/d agonist), GW4148 (a/d/g pan
agonist), and GW0072 (antagonist). 13-cis RA was obtained from
Sigma (St Louis, MO) and the PPAR agonists rosiglitazone and
pioglitazone were obtained from Cayman Chemical Company (Ann
Arbor, MI). All ligands were solubilized in DMSO.
Lipogenesis assay: 14C-acetate incorporation into neutral lipids
SEB-1 sebocytes were treated with PPAR ligands and 13-cis RA at
concentrations listed in Table 2 and were assayed for the
incorporation of 14C-acetate into neutral lipids. Preliminary dose–
response studies were performed with three doses chosen around the
reported Km’s for these compounds. The doses shown in Table 2
represent data obtained with the highest dose. Three experiments
were performed at three different days for each ligand tested. SEB-1
cells were cultured in standard medium until confluent. Cells were
then treated every 3 days over a 6-day period with either a PPAR
ligand in serum free medium or serum free medium with 0.1%
DMSO as a negative control. Cells were treated with 13-cis RA for
72 hours as marked cell death occurs with longer time points. Cells
were then collected with trypsin and an aliquot taken for a cell count
that was used to normalize the data. The remaining cells were
suspended in a solution containing 1mCi of 14C-acetate in either
DMEM alone (5.5 mM glucose) or DMEM (5.5 mM glucose) contain-
ing varying concentrations of the compound to be tested and
incubated for 2 hours at 371C. Lipids were extracted, separated with
thin layer chromatography and subjected to liquid scintillation
counting according to methods in place in our laboratory (Smith
et al., in press). Acetate incorporation into lipids was expressed as
c.p.m. 14C-acetate incorporated/106 cells/hour.
Statistical analyses
Sebum assessments in patients treated with topical fibrates
and thiazolidinediones. Using a predetermined assessment of the
variability in sebum measurements, a sample size determination was
performed for the assessment of sebum production in patients treated
with fibrates or thiazolidinediones. With 75 subjects in each group
(control, thiazolidinedione, or fibrate), there would be a 90% power
to detect a 20% change in sebum. Two-sided unpaired t-tests
(a¼ 0.05) were performed to look for differences in sebum excretion
between: (1) thiazolidinedione and matched control group and (2)
fibrate and matched control group. The effect size of 20% used to
determine the sample size was chosen by conjecture and not based
on historical data. Therefore, interim analyses were planned at fixed
time intervals during study enrollment so that recruitment would be
stopped if the accumulated data provided evidence that the true
effect size was larger than 20%.
Lipogenesis assays in SEB-1 sebocytes treated with PPAR
ligands and 13-cis RA. To test for the null hypothesis of equal lipid
levels in control group and groups treated with compounds, repeated
measures analysis of variance models with terms indicating date
when the experiments were done, treatment and date by treatment
interaction effects were used to fit the data. All analyses were done
using computer package SAS version 8 (SAS Institute Inc., Cary, NC).
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